GSK CEO Walm­s­ley is re­or­ga­niz­ing R&D, drop­ping drugs and adding a new fo­cus on can­cer re­search

Just days af­ter rush­ing Dana-Far­ber chief Lau­rie Glim­ch­er on­to the board at Glax­o­SmithK­line $GSK, new CEO Em­ma Walm­s­ley is mak­ing her move to re­or­ga­nize the pipeline. Her plan calls for a ma­jor R&D cull, drop­ping 30 de­vel­op­ment projects and adding can­cer and im­muno-in­flam­ma­to­ry dis­eases to its list of top R&D pri­or­i­ties — which will con­sume the li­on’s share of its bud­get.

Em­ma Walm­s­ley

In a state­ment out ear­ly Wednes­day, GSK out­lined plans to part­ner out or sim­ply drop 30 pre­clin­i­cal and clin­i­cal pro­grams, stream­lin­ing R&D and oth­er op­er­a­tions in the glob­al op­er­a­tion as the com­pa­ny looks for about $1.3 bil­lion in sav­ings by 2020. Rare dis­ease drugs in par­tic­u­lar ap­pear to be on the chop­ping block while a list of as­sets that are be­ing dropped from the pipeline in­cludes sirukum­ab, its dis­ap­point­ing rheuma­toid arthri­tis drug now un­der reg­u­la­to­ry re­view and part­nered with J&J $JNJ.

You can see the full list be­low.

The move puts GSK back in play as sev­er­al top bio­phar­ma com­pa­nies look to shake up their R&D or­ga­ni­za­tions and start to strike new deals. And the phar­ma gi­ant’s re­turn to the deal ta­ble will quick­ly earn close at­ten­tion from a long list of ri­vals. More big play­ers are al­so like­ly to fol­low suit, mark­ing a turn­ing point for bio­phar­ma as a slate of new CEOs look to put their dis­tinc­tive stamp on prod­uct de­vel­op­ment.

The plan at Glax­o­SmithK­line now is to re­serve about 80% of its an­nu­al multi­bil­lion-dol­lar bud­get for two main­stay dis­ease fields — res­pi­ra­to­ry and HIV/in­fec­tious dis­eases — while ex­am­in­ing the “po­ten­tial” ad­di­tion of can­cer and im­muno-in­flam­ma­tion. GSK spent $4.5 bil­lion on R&D, putting it among the top 15 in the in­dus­try.

The phar­ma gi­ant al­so plans to get its busi­ness de­vel­op­ment team back to the bar­gain­ing ta­ble af­ter a long ab­sence in search of new, pri­mar­i­ly ear­ly-stage deals.

Walm­s­ley in­her­it­ed one of the weak­est R&D groups in Big Phar­ma when she took the helm in April. De­spite sig­nif­i­cant progress in HIV and vac­cines, phar­ma R&D lan­guished af­ter a pe­ri­od marked by some high-pro­file flame­outs in Phase III de­vel­op­ment. Now the CEO wants to use the stream­lin­ing to set up a re­vival for the phar­ma re­search group.

From their quar­ter­ly state­ment:

In its Phar­ma­ceu­ti­cals pipeline, GSK has de­vel­oped a pri­or­i­ty list of as­sets to in­vest be­hind. This pri­or­i­ty list will evolve as da­ta reads out. The Group has al­so set a tar­get to de­ploy over time 80% of its Phar­ma­ceu­ti­cals R&D cap­i­tal to pri­or­i­ty as­sets in two cur­rent ther­a­py ar­eas: Res­pi­ra­to­ry and HIV/in­fec­tious dis­eases; and two po­ten­tial ar­eas: On­col­o­gy and Im­muno-in­flam­ma­tion. Sig­nif­i­cant da­ta is ex­pect­ed from these pri­or­i­ty as­sets over the next three years which will be used to in­form R&D in­vest­ment de­ci­sions and how best to gen­er­ate val­ue from these as­sets. GSK al­so ex­pects to pur­sue dis­ci­plined busi­ness de­vel­op­ment to aug­ment its ear­ly-stage pipeline in these pri­or­i­ty ar­eas.

Now in the spot­light at GSK: A range of Phase I and Phase II can­cer drugs, in­clud­ing its mid-stage pro­gram part­nered with Adap­ti­m­mune $ADAP.

J&J says that GSK’s de­ci­sion to bail out on sirukum­ab leaves them in charge of world­wide roll­out, and they have no plans to change course now. In a state­ment to End­points News, the com­pa­ny not­ed:

Our pri­or­i­ty is work­ing with Health Au­thor­i­ties in the U.S., Eu­rope, Japan and many oth­er coun­tries to bring this nov­el an­ti-IL-6 mon­o­clon­al an­ti­body to RA pa­tients.  We are con­tin­u­ing with launch prepa­ra­tions in EMEA and Asia Pa­cif­ic through our world-class Janssen Im­munol­o­gy or­ga­ni­za­tion, and we are al­so ex­plor­ing the best op­por­tu­ni­ties to bring this im­por­tant new med­i­cine to pa­tients in the ge­o­gra­phies that will re­turn to Janssen.

The move at GSK mir­rors the same ba­sic strat­e­gy that Michel Vounatsos and Dave Ricks an­nounced yes­ter­day for Bio­gen and Eli Lil­ly. Both have been lay­ing plans to “stream­line” op­er­a­tions and de­vote more time to new projects that can whip up some ex­cite­ment among the in­vestor crowd. Lil­ly al­so is drop­ping can­cer projects — while GSK looks to add to what’s left of its on­col­o­gy group fol­low­ing a big trade­off with No­var­tis.

These moves will cre­ate dozens of new busi­ness op­por­tu­ni­ties among biotech play­ers look­ing for new as­sets to pick over. Typ­i­cal­ly these projects go for on­ly small amounts of up­front cash. And it al­so adds new play­ers to the deal ta­ble, ready to spend cash and part­ner on more drugs.

GSK sig­naled this move re­cent­ly af­ter it re­cruit­ed Glim­ch­er to its board. The im­muno-on­col­o­gy ex­pert joined the board’s sci­ence team and can of­fer some key in­sights gleaned from years on the board at Bris­tol-My­ers Squibb.

From the GSK pre­sen­ta­tion:

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Gen­mab ax­es an ADC de­vel­op­ment pro­gram af­ter the da­ta fail to im­press

Genmab $GMAB has opted to ax one of its antibody-drug conjugates after watching it flop in the clinic.

The Danish biotech reported Tuesday that it decided to kill their program for enapotamab vedotin after the data gathered from expansion cohorts failed to measure up. According to the company:

While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers. Accordingly, the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

Novartis is always one of the industry’s biggest R&D spenders. As they often do toward the end of each year, company execs are highlighting the drugs they expect will most likely be winners in 2021.

And they’re also dreaming about some potential big-time lottery tickets.

As part of its annual investor presentation Tuesday, where the company allows investors and analysts to virtually schmooze with the bigwigs, Novartis CEO Vas Narasimhan will outline what he thinks are the pharma’s “Wild Cards.” The slate of five experimental drugs are those that Novartis hopes can be high-risk, high-reward entrants into the market over the next half-decade or so, and cover a wide range of indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bahija Jallal (file photo)

TCR pi­o­neer Im­muno­core scores a first with a land­mark PhI­II snap­shot on over­all sur­vival for a rare melanoma

Bahija Jallal’s crew at TCR pioneer Immunocore says they have nailed down a promising set of pivotal data for their lead drug in a frontline setting for a solid tumor. And they are framing this early interim readout as the convincing snapshot they need to prove that their platform can deliver on a string of breakthrough therapies now in the clinic or planned for it.

In advance of the Monday announcement, Jallal and R&D chief David Berman took some time to walk me through the first round of Phase III data for their lead TCR designed to treat rare, frontline cases of metastatic uveal melanoma that come with a grim set of survival expectations.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

News brief­ing: Gilead part­ner Gala­pa­gos sells off CRO for $37M; Polyphor bags $3.3M from CF Foun­da­tion

Close Gilead ally Galapagos is selling off one of its contract research organizations to a Polish pharma company.

Galapagos has agreed to sell 100% of the outstanding shares in the CRO Fidelta to Selvita, in a deal worth roughly $37 million expected to close in the first week of January. The acquisition is expected to nearly double Selvita’s revenues, the company says, as well as expand its drug discovery efforts.